Alkermes plc (NasdaqGS: ALKS)
Health Care · Biotechnology · IE
$40.38
-0.57% today · +29.4% 1Y
Alkermes plc (NasdaqGS: ALKS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.81B and employs 2,050 people.
Over the last twelve months the share price has gained 29.4%, trading between 27.00 and 55.67.
Tweenvest scores Alkermes plc across four factors: quality 80/100, value 23/100, growth 51/100. Its strongest factor is quality.
ALKS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.81B
- Revenue (TTM)
- $1.67B
- P/E
- 104.60
- EPS
- 0.39
- Dividend yield
- —
- Beta (5Y)
- 0.27
- 52-week high
- $55.67
- 52-week low
- $27.00
- Avg volume (3M)
- —
- Shares outstanding
- 167.76M
- Employees
- 2,050
- Next earnings
- —
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
- ISIN
- IE00B56GVS15
- Founded
- 1987
- Listed since
- Jul 16, 1991
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ABIVAX Société AnonymeENXTPA: ABVX | $7.71B | €79.00 | +2.46% |
| RemeGen Co., Ltd.SEHK: 9995 | $7.56B | HK$70.40 | -3.43% |
| Ionis Pharmaceuticals, Inc.NasdaqGS: IONS | $7.52B | $44.13 | -2.54% |
| Praxis Precision Medicines, Inc.NasdaqGS: PRAX | $7.26B | $254.06 | -2.23% |
| Biocytogen Pharmaceuticals (Beijing) Co., Ltd.SEHK: 2315 | $6.75B | HK$69.20 | +2.59% |
| Gan & Lee Pharmaceuticals.SHSE: 603087 | $6.71B | CN¥75.52 | -2.43% |
| Iovance Biotherapeutics, Inc.NasdaqGM: IOVA | $6.62B | $14.61 | -0.10% |
| Grifols, S.A.BME: GRF | $6.62B | €10.02 | +1.42% |
Figures last refreshed Oct 11, 2026.